<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180416039326N18</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-08</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effects of sublingual fentanyl and intravenous ketamine in phacoemulsification cataract surgery</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effects of sublingual fentanyl and intravenous ketamine on pain control and hemodynamic variables in phacoemulsification cataract surgery under sedation and local anesthesia</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>86</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54183</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In the operating room, based on a random allocation software table , one of the compounds of sublingual fentanyl or intrvenous ketamine is given to patients, Blinding description: The patient and the researcher are not aware of the type of medication used. Medications are prepared by an anesthetic expert who has no role in the study and then injected by an anesthetist to each patient group. The person who records the data is also unaware of the type of medication used.</study_design>
      <phase>2</phase>
      <hc_freetext>cataract surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the sublingual fentanyl (SLF) group, fentanyl at a dose of 1.5µ / kg (up to 100 micrograms), which is reduced to 2 ml with normal saline, is administered sublingually to the patient. first 2 cc fentanyl (up to 100 micrograms) is administered sublingually. After 10 minutes, we ask patients to remove the contents of their mouth and then 2 cc of normal saline is injected intravenously. To induce sedation propofol (1%) 15 ml, which is reduced to 20 cc with 5 cc of 5% dextrose (containing propofol 7.5 mg / ml) by infusion with a pump at a rate of 0.4 ml per Weight per hour to receive propofol at a sedative dose of 50 micrograms per kilogram of body weight per minute. If further sedation is required, a rescue dose of 2 cc propofol at a concentration of 5 mg / cc will be given as a bolus. Intervention 2: Control group: In intravenous ketamine (IVK) group, first 2 cc of normal saline is administered sublingually. After 10 minutes, we ask patients to remove the contents of their mouth and then ketamine at a dose of 0.3 mg / kg which is reduced to 2 ml with normal saline is injected intravenously. To induce sedation propofol (1%) 15 ml, which is reduced to 20 cc with 5 cc of 5% dextrose (containing propofol 7.5 mg / ml) by infusion with a pump at a rate of 0.4 ml per Weight per hour to receive propofol at a sedative dose of 50 micrograms per kilogram of body weight per minute.   If further sedation is required, a rescue dose of 2 cc propofol at a concentration of 5 mg / cc will be given as a bolus.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Unidentifiable individual data can be shared.

When:
6 months after publication of paper

To whom:
Only available to scholars working in academic and academic institutions

Conditions:
Use for research and treatment purposes

Where to obtain:
Email of the person in charge of public accountability: Hamidshetabi@med.mui.ac.ir

How to obtain:
after request via email, it will be sent if available within a maximum of 1 month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamidreza Shetabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feyz hospital, Modares St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3668 8138</telephone>
        <email>Hamidshetabi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamidreza Shetabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Feyz hospital, Modarres St</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3668 8138</telephone>
        <email>Hamidshetabi@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients aged 50-75 with ASA (American Society of Anesthesiology) class 1 and 2 that Candidates for phycoemulsification cataract surgery who are willing to enter the study</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of any allergy or allergic reaction to any of medications used in the study
pregnancy
seizure or psychotic  disorder
preoperative hypotention
Taking medication preoperatively (other than those mentioned before)
Inflammation or any lesion of the oral cavity that interferes with sublingual administration of the drug
increase intracranial pressure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>H26.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Unspecified cataract</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the sublingual fentanyl (SLF) group, fentanyl at a dose of 1.5µ / kg (up to 100 micrograms), which is reduced to 2 ml with normal saline, is administered sublingually to the patient. first 2 cc fentanyl (up to 100 micrograms) is administered sublingually. After 10 minutes, we ask patients to remove the contents of their mouth and then 2 cc of normal saline is injected intravenously. To induce sedation propofol (1%) 15 ml, which is reduced to 20 cc with 5 cc of 5% dextrose (containing propofol 7.5 mg / ml) by infusion with a pump at a rate of 0.4 ml per Weight per hour to receive propofol at a sedative dose of 50 micrograms per kilogram of body weight per minute. If further sedation is required, a rescue dose of 2 cc propofol at a concentration of 5 mg / cc will be given as a bolus.</i_keyword>
      <i_keyword>Control group: In intravenous ketamine (IVK) group, first 2 cc of normal saline is administered sublingually. After 10 minutes, we ask patients to remove the contents of their mouth and then ketamine at a dose of 0.3 mg / kg which is reduced to 2 ml with normal saline is injected intravenously. To induce sedation propofol (1%) 15 ml, which is reduced to 20 cc with 5 cc of 5% dextrose (containing propofol 7.5 mg / ml) by infusion with a pump at a rate of 0.4 ml per Weight per hour to receive propofol at a sedative dose of 50 micrograms per kilogram of body weight per minute.   If further sedation is required, a rescue dose of 2 cc propofol at a concentration of 5 mg / cc will be given as a bolus.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Sedation level based on ramsay score. Timepoint: every 5 minutes during surgery and then in recovery every 15 minutes, until discharge from recovery. Method of measurement: Ramsay score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Arterial blood pressure. Timepoint: Before surgery, during surgery every 5 minutes and in recovery every 15 minutes, until discharge from recovery. Method of measurement: pressure gauge.</sec_outcome>
      <sec_outcome>Oxygen saturation. Timepoint: Before surgery, during surgery every 5 minutes and in recovery every 15 minutes, until discharge from recovery. Method of measurement: Pulse oximeter.</sec_outcome>
      <sec_outcome>Heart rate. Timepoint: Before surgery, during surgery every 5 minutes and in recovery every 15 minutes, until discharge from recovery. Method of measurement: Pulse oximeter.</sec_outcome>
      <sec_outcome>Intensity of pain. Timepoint: in recovery every 15 minutes, until discharge from recovery. Method of measurement: Universal Pain assessment tool.</sec_outcome>
      <sec_outcome>Recovery time. Timepoint: After surgery until the discharge from the recovery. Method of measurement: Minute Numbers.</sec_outcome>
      <sec_outcome>Patient satisfaction. Timepoint: At the time of discharge from recovery. Method of measurement: Likert questionnaire.</sec_outcome>
      <sec_outcome>Surgeon satisfaction. Timepoint: after surgery. Method of measurement: Likert questionnaire.</sec_outcome>
      <sec_outcome>Adverse drug reaction. Timepoint: During surgery and in recovery. Method of measurement: Adverse drug reaction questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Isfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-05-02</approval_date>
        <contact_name>Ethics committe of Isfahan University of Medical Sciences</contact_name>
        <contact_address>Isfahan University of Medical Sciences and Health Services, Building No.4, Research and Technology Deputy of University,Hezar Jarib Street, Isfahan,Iran Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
